Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia
- MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
- Cladribine capsules have the potential to be the first oral treatment for gMG patients
- gMG is a rare, chronic autoimmune neuromuscular disorder that results in muscle weakness in the eyes, mouth, throat, and limbs
DARMSTADT, Germany -- (BUSINESS WIRE) --
Not intended for UK-, US- or Canada-based media
Merck, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis (gMG). Cladribine capsules have the potential to be the first oral treatment for gMG patients. gMG is a rare, neuromuscular disorder causing muscle weakness that can be severe and have a significant impact on patients’ lives.
Cladribine is expected to selectively target B and T lymphocytes. These cells are thought to be the root cause of gMG through the production of the harmful autoantibodies that drive inflammation at the connection points between nerves and muscles. This mechanism of action coupled with a short course oral dosing taken at home may ultimately slow the progression of the disease by targeting its underlying cause while diminishing treatment burden.
“Given our extensive experience in addressing patients’ needs in immune-driven neurological conditions, we believe that cladribine capsules represent a highly differentiated potential therapeutic option for gMG,” said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck KGaA, Darmstadt, Germany. “This treatment approach holds the promise of achieving a high degree of disease activity control, offering greatly improved convenience, and ultimately enabling patients to live their lives as normally as possible.”
MyClad is a global Phase III, randomized, double-blind and placebo-controlled study designed to assess the efficacy and safety of cladribine capsules in 240 patients with gMG.
About generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, impacting an estimated 700,000 people worldwide. The disease can strike anyone at any age but is more frequently seen in young women (age 20 to 30) and men aged 50 and older. In gMG, the communication between the nerves and the muscles, particularly at the neuromuscular junction (NMJ), is disrupted causing muscle weakness. This can result in the loss of control in the eye muscles and a variable combination of the arms, legs, and respiratory muscles. The unpredictable severity and frequency of symptoms in gMG patients can be debilitating, significantly impacting various aspects of day-to-day life.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company’s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG).
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
- Ingredion Incorporated Reports Strong 2023 Fourth Quarter and Full-Year Results
- 陈学文董事长:打造百亿级花椒交易市场,服务百万亩花椒产业基地
- 东莞市金穗汇服饰有限公司——定制随心,品味私享
- 中国人保为金诺防水承保产品责任险,为消费者保驾护航!
- 国美控股集团与帅猫体育联手打造全新台球娱乐场所
- “AI赋能 产业换新”愿景娱乐获“年度商业价值荣誉电商机构”奖
- JEOL : - A Useful Tool for Every User! - New Electron Microscope JEM-120i Released
- 周六福品牌价值突破362.15亿,九度蝉联荣耀,稳居中国500强品牌之列!
- instagram批量私信营销工具,ins快速批量私信软件
- Vital Voices Kicks Off Women’s History Month with an Interactive Art Exhibit at the United Nations a
- 波司登“融”概念秀闪耀法国巴黎 揭开东方时尚长卷
- 平安养老险陕西分公司:反保险欺诈案例(二)——打击保险欺诈,守护金融安全
- Floship 荣获德勤新星奖
- 飞驰环球欧陆景行庆祝中俄文化年书画名家联展走进莫斯科
- 优悦繁景艺术中心又开新店,投资近亿元,20000平米
- Survey Reveals Accountants Play Vital Role In Driving Financial Transformation for Organizations
- 第八届丝绸之路金色年华全国风采大赛暨国潮华服时装周圆满落幕
- Asyatt. Inc.: 开始筹资20亿日元
- 数字素养 ,教师与教育高质量发展的新引擎
- CRO企业选择魔方网表作为数字化转型平台的十大理由
- 海信5G+荣耀家中央空调让健康智慧空气随心而至
- Fluence Expands Presence in Asia-Pacific Region, Opens Local Office in Taiwan
- “AI+”加什么?老板电器的答案很有烟火气
- 拒绝”接闪“雷电 保护一方平安 再访世界著名防雷科学家濮方正
- 粤港联动,北斗高质量国际化发展的重要机遇
- 2024HOPE幼教创新大会顺利召开!
- 中国农副产业:传承千年农耕文化,铸就绿色健康生活
- 知名眼整形专家成璞加盟福州爱尔眼科医院,开启“睛”彩篇章 “个性化眼部整形工作站”成立
- 2024年度中国百强艺术家榜单——丁六五作品鉴赏
- Bureau Veritas Acquires Security Innovation Inc. to Reinforce Its Cybersecurity Expertise in the Sof
推荐
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯